Log on / register
Feedback | Support | My details

Email this article to a friend

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

Sean P Dineen email, Laura A Sullivan email, Adam W Beck email, Andrew F Miller email, Juliet G Carbon email, Roni Mamluk email, Henry Wong email and Rolf A Brekken email

BMC Cancer 2008, 8:352doi:10.1186/1471-2407-8-352

Your name*
Your email address*
Recipient's email address*
(multiple email addresses should be separated with commas)
Email format
Please type your message into the box below:
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.